ArticleRMD open2016
Costs of drugs for treatment of rheumatic diseases.
Article in RMD open, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- From Methotrexate Resistance to Biologic and Targeted Pharmacotherapy: A Decade of Phase 4 Clinical Trials Evidence in Rheumatoid Arthritis.Drug design, development and therapy · 2026Pooled it
- Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction.Annals of the rheumatic diseases · 2020Trial
- Maintained improvement in patient-reported outcomes in early axial spondyloarthritis following certolizumab pegol dose reduction: findings from the randomised period of a phase 3b trial.EULAR rheumatology open · 2026Article
- Treating rheumatoid arthritis in Zanzibar: a cost effectiveness study comparing conventional, biologic, and targeted-synthetic disease modifying anti-rheumatic drugs.Frontiers in medicine · 2025Article
- Cost of treating rheumatoid arthritis in the primary care public health system in Ireland: A time-driven activity-based cost analysis.Exploratory research in clinical and social pharmacy · 2024Article
- TCM nonpharmacological interventions for ankylosing spondylitis: A protocol for systematic review and network meta-analysis.Medicine · 2021Article
- Off-Patent Biological and Biosimilar Medicines in Belgium: A Market Landscape Analysis.Frontiers in pharmacology · 2021Article
- The Efficacy and Safety of Simple-Needling Therapy for Treating Ankylosing Spondylitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Evidence-based complementary and alternative medicine : eCAM · 2020Review
- Clinical efficacy of new JAK inhibitors under development. Just more of the same?Rheumatology (Oxford, England) · 2019Review
- Effectiveness of Subcutaneous Tumor Necrosis Factor Inhibitors in Patients With Ankylosing Spondylitis: A Real-World Prospective Observational Cohort Study in China.Frontiers in pharmacology · 2019Article
- Cost evolution of biological agents for the treatment of spondyloarthritis in a tertiary hospital: influential factors in price.International journal of clinical pharmacy · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The cost of drugs is becoming an issue worldwide, in particular for inflammatory rheumatic diseases. In the current review, an overview of the scene is given with a specific emphasis on accessibility for those patients in real need of the available expensive treatments. The authors propose 7 principles for discussion that need to be addressed and are a responsibility for all stakeholders in rheumatology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.